Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SBIO Pte. Ltd.

www.sbio.com

Latest From SBIO Pte. Ltd.

Sanofi kills PhIII JAK2 inhibitor on safety grounds

Sanofi has called an immediate halt to all trials of fedratinib (SAR302503) following reports of neurological side-effects. The company had reported positive Phase III results for the JAK2 inhibitor in myelofibrosis earlier this year. Now, however, it says it is cancelling all plans for regulatory filings.

Deals Of The Week Discusses Pharma’s Need For Disruptive Collaboration

Two CEOs describe their approach to virtual partnerships, corporate renewal, and active risk management. Plus, more conventional divestment and M&A deals from Novartis and Grifols and Roche and immatics.

BioPharmaceutical France

Deals of the Week: Options Abound As Forest Keeps Its Eyes On A Prize-Winner

Reflecting a long trend, three of this past week’s deals include option arrangements, including one with a new twist. Also, a rare disease partnership between Shire and Atlas Venture finally leads to a deal and Takeda continues building its vaccines business.

BioPharmaceutical Deals

Deals Of The Week: Exit From Ambit Tie-Up Just A Blip In Astellas’ Oncology Aspirations

DOTW looks at Astellas’ oncology ambitions plus its recent split with partner Ambit, as well as analysis of Shire’s buyout of Premacure, AbbVie’s out-license of an anti-interleukin-13 antibody to Receptos and the Merck/Luminex collaboration on a companion diagnostic for Alzheimer’s disease.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • S*BIO Pte. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Southeast Asia
        • Singapore
  • Parent & Subsidiaries
  • SBIO Pte. Ltd.
  • Senior Management
  • Tamar Howson , Interim CEO
    Kantharaj Ethirajulu, Head, Preclin. Dev.
  • Contact Info
  • SBIO Pte. Ltd.
    Phone: (65) 6827 5000
    1 Science Park Rd., #05-09 The Capricorn
    Science Pk. 2
    , 117 528
    Singapore
Advertisement
Advertisement
UsernamePublicRestriction

Register